Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Peter Greenleaf Sells 797 Shares

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $26.13, for a total value of $20,825.61. Following the transaction, the director owned 23,884 shares in the company, valued at approximately $624,088.92. This trade represents a 3.23% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Stock Performance

Shares of Pelthos Therapeutics stock traded up $0.27 on Tuesday, reaching $24.60. The stock had a trading volume of 36,589 shares, compared to its average volume of 15,341. The business has a 50-day moving average price of $26.73. The company has a current ratio of 2.79, a quick ratio of 1.86 and a debt-to-equity ratio of 1.41. Pelthos Therapeutics Inc. has a fifty-two week low of $16.09 and a fifty-two week high of $37.50. The company has a market capitalization of $85.61 million, a PE ratio of -1.19 and a beta of 3.10.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The company had revenue of $10.91 million for the quarter. As a group, equities analysts forecast that Pelthos Therapeutics Inc. will post -12.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pale Fire Capital SE raised its position in shares of Pelthos Therapeutics by 59.5% during the first quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock valued at $271,000 after buying an additional 4,819 shares during the last quarter. Knott David M Jr grew its position in Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after buying an additional 1,792 shares in the last quarter. Ikarian Capital LLC increased its stake in Pelthos Therapeutics by 309.5% during the fourth quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after acquiring an additional 193,307 shares during the period. Millennium Management LLC acquired a new position in Pelthos Therapeutics in the 4th quarter valued at approximately $343,000. Finally, Boothbay Fund Management LLC lifted its position in shares of Pelthos Therapeutics by 279.8% in the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock worth $2,501,000 after acquiring an additional 59,435 shares during the period. Institutional investors own 77.96% of the company’s stock.

Analysts Set New Price Targets

PTHS has been the topic of a number of recent analyst reports. Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating and a $50.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Zacks Research raised Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Finally, Oppenheimer upped their price target on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.80.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).